The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2019 | CAR-T in myeloma: what is the potential?
CAR T-cell therapy is a growing immunotherapy, but what is its potential for multiple myeloma? Philip McCarthy, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses the recent trial of idecabtagene vicleucel (ide-cel; bb2121; NCT03274219) and the questions it leaves to be answered, including whether CAR-T is most beneficial during first relapse or as part of consolidation after transplant. Additionally, Prof. McCarthy discusses the options for poor response patients. One thing is clear, it will be an interesting journey. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.
